Singapre's Healint, the developer of the world’s largest digital patient hub with 1,3 million users and 300 million tracked health events, has made a series of senior appointments to meet the strongly growing demand for its healthcare predictive analytics. The company announced the appointment of pharma industry veteran Maryline Marquet as Chief Commercial Officer.

Maryline Marquet joins Healint’s leadership team as Chief Commercial Officer overseeing the company’s sales, marketing and business development. Mrs. Marquet’s extensive experience comprises senior positions at Janssen Pharmaceuticals, Becton Dickinson and International SOS in Europe and Singapore.

Speaking at the SGInnovate event ‘Health Tech Startups - How to Make it Work Globally’ on October 2nd 2018, Healint’s CEO Francois Cadiou commented on this appointment: ‘Maryline is a fantastic global digital health leader with an in-depth knowledge of numerous conditions, and the commercialisation of digital services around them. We are truly excited to have her on our team as Healint is expanding its predictive analytics service offering and the spectrum of conditions covered on our HEALE AI platform.’

Maryline Marquet says: ‘I am delighted to join Healint, as the company has already achieved a global leadership position in Patient Reported Outcomes (PRO) across several medical conditions. This is testament to the company’s ability to engage patients on continuous basis and to transform insights solutions to include predictives. I commend the Healint team for their remarkable accomplishments with migraine, and look forward to replicating these successes in many other disease areas with unmet needs.’

Further hires at Healint include Anna Nayoung Park, who joins Healint’s product management team from Asia’s leading chat platform ‘Line’, and Bo Zhang, previously a Program Manager at Human Care Systems and a nurse at Changi General Hospital, Singapore. With the strongly growing team, Healint recently relocated its head office to 100 Pasir Panjang, Singapore.